Clinical Trial

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 27, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-01-18; most recent amendment 2024-12-22.
Status change: Not Yet Recruiting → Recruiting 2023-03-01
Trial Details
NCT Number NCT05690581
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Advanced Solid Tumors and Hematologic Malignancies
Enrollment 146 participants
Start Date 2023-02-23
Primary Completion 2025-10-30 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-12-27